The investigations follow complaints filed by two former Theranos employees, casting even greater doubt upon the honesty and accuracy of the $9 billion blood test startup.
The $9 billion blood-test startup is facing allegations that it's struggling with its ostensibly groundbreaking tech. But is it taking the right approach to responding to the crisis?